Bayer Schering Pharma AG and Bayer (Pty) Ltd v Pharma Dynamics and The Registrar of Patents
Yasmin* is the trade name for drospirenone and ethinyl estradiol, used mainly as an oral contraceptive.
It is also indicated in the treatment of acne. According to reports in Bloomberg, Yasmin was the number four oral contraceptive in the US during 2011. Bayer AG’s contraceptives generated $1.58 billion in sales in 2010—a sizable market by any measure.
Internationally, and particularly in the US, Yasmin has been the subject matter of class action litigation. It has also been the subject of patent litigation in South Africa. An action for the infringement of South African patent 2004/4083 was instituted against Pharma Dynamics in response to approval by the Medicines Control Council to market a competing generic product, Ruby, in South Africa.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
Yasmin, oral contraceptive, patent, South Africa